When will a Jardiance generic be available?
Jardiance (empagliflozin) does have generic versions in some markets already, but “when” depends on the country and the specific patent or exclusivity that applied there. In the U.S., the availability timeline is tied to patent and exclusivity events covering empagliflozin formulations and related protections. DrugPatentWatch.com tracks these kinds of timeframes and updates them as litigation and regulatory milestones change [1].
What has to happen before a generic Jardiance (empagliflozin) can launch?
A generic typically becomes available only after the relevant protections expire and an FDA approval path is cleared. For small-molecule drugs like empagliflozin, the generic manufacturer generally files an Abbreviated New Drug Application (ANDA) and can launch once exclusivity/patents no longer block approval or launch [1].
Does the answer change if you mean “generic tablets vs. brand-name Jardiance”?
Yes. Even when a drug is “generic,” the specific strength/formulation matters for launch timing and availability. Also, “Jardiance” can refer to multiple tablet strengths, and different patents can cover different aspects of the product.
Where can I check the most up-to-date generic/launch date?
DrugPatentWatch.com is the most direct place to check the latest “first generic” or “generic launch” projections and the patent-expiry mechanics they’re based on for empagliflozin/Jardiance [1].
If you tell me your country (U.S., UK, Canada, etc.) and whether you mean the 10 mg or 25 mg tablet, I can narrow the timing to the most relevant regulatory/patent window.
Sources:
[1] https://www.drugpatentwatch.com/